Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 28Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 23Carcinoma, Hepatocellular 22Colorectal Neoplasms 19Triple Negative Breast Neoplasms 16Pancreatic Neoplasms 15Neoplasms 15Stomach Neoplasms 14Squamous Cell Carcinoma of Head and Neck 13Nasopharyngeal Carcinoma 13Carcinoma, Renal Cell 13Uterine Cervical Neoplasms 10Rectal Neoplasms 10Lymphoma 8Sarcoma 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Recurrence 6Lymphoma, Extranodal NK-T-Cell 6Lung Neoplasms 6Locally Advanced Rectal Cancer 6Breast Neoplasms 6Advanced Solid Tumor 6Ovarian Neoplasms 5Liver Neoplasms 5Glioblastoma 5Endometrial Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4

Interventions

Gemcitabine 2spartalizumab 1sargramostim 1folfirinox 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Pancreaticoduodenectomy 1Magnetic Resonance Spectroscopy 1Leucovorin 1Laparoscopy 1Fluorouracil 1Drug Therapy 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Pancreatic Adenocarcinoma × spartalizumab × Clear all
NCT05607953 2025-07-04

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

TriSalus Life Sciences, Inc.

Phase 1 Active not recruiting
60 enrolled
Gastrointestinal

Locally Advanced Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡